Li-xian Wu1, Ying Wu2, Rui-jia Chen3, Yang Liu4, Li-sen Huang3, Li-guang Lou5, Zhi-hong Zheng6, Yuan-zhong Chen6, Jian-hua Xu1. 1. 1] Department of Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [3] Fuijan Key Laboratory of Natural Medicine Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China. 2. 1] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Fuijan Key Laboratory of Natural Medicine Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China. 3. 1] Department of Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China. 4. 1] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Fuijan Key Laboratory of Natural Medicine Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [3] Department of pharmacochemistry, School of pharmacy, Fujian Medical University, Fuzhou 350004, China. 5. Shanghai Institute of Materia Medica, Shanghai 201203, China. 6. Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou 350001, China.
Abstract
AIM: To find new kinase inhibitors that overcome the imatinib resistance in treatment of chronic myeloid leukemia (CML), we synthesized C817, a novel derivative of curcumin, and tested its activities against wild-type (WT) and imatinib-resistant mutant Abl kinases, as well as in imatinib-sensitive and resistant CML cells in vitro. METHODS: 32D cells harboring WT or mutant Abl kinases (nucleotide binding P-loop mutants Q252H, Y253F, and imatinib contact residue mutant T315I), as well as K562/G01 cells (with whole Bcr-Abl gene amplication) were tested. Kinase activity was measured using Kinase-Glo Luminescent Kinase Assay Platform in recombinant WT and mutant (Q252H, Y253F, and T315I) Abl kinases. Cell proliferation and apoptosis were examined using MTT assay and flow cytometry, respectively. The phosphorylation levels of Bcr-Abl initiated signaling proteins were analyzed using Western blotting. Colony forming units (CFU) growth and long term culture-initiating cells (LTC-ICs) were used to test the effects of C817 on human leukemia progenitor/stem cells. RESULTS: C817 potently inhibited both WT and mutant (Q252H, Y253F, and T315I) Abl kinase activities in a non-ATP competitive manner with the values of IC₅₀ at low nanomole levels. In consistent with above results, C817 suppressed the growth of both imatinib-sensitive and resistant CML cells, including wild-type K562, K562/G01, 32D-T315I, 32D-Q252H, and 32D-Y253F cells with the values of IC₅₀ at low micromole levels. C817 (0.5 or 1 μmol/L) dose-dependently inhibited the phosphorylation of Bcr-Abl and downstream proteins STAT-5 and CrkL in imatinib-resistant K562/G01 cells. Furthermore, C817 significantly suppressed CFU growth and LTC-ICs, implicating that C817 could eradiate human leukemia progenitor/stem cells. CONCLUSION: C817 is a promising compound for treatment of CML patients with Bcr-Abl kinase domain mutations that confer imatinib resistance.
AIM: To find new kinase inhibitors that overcome the imatinib resistance in treatment of chronic myeloid leukemia (CML), we synthesized C817, a novel derivative of curcumin, and tested its activities against wild-type (WT) and imatinib-resistant mutant Abl kinases, as well as in imatinib-sensitive and resistant CML cells in vitro. METHODS: 32D cells harboring WT or mutant Abl kinases (nucleotide binding P-loop mutants Q252H, Y253F, and imatinib contact residue mutant T315I), as well as K562/G01 cells (with whole Bcr-Abl gene amplication) were tested. Kinase activity was measured using Kinase-Glo Luminescent Kinase Assay Platform in recombinant WT and mutant (Q252H, Y253F, and T315I) Abl kinases. Cell proliferation and apoptosis were examined using MTT assay and flow cytometry, respectively. The phosphorylation levels of Bcr-Abl initiated signaling proteins were analyzed using Western blotting. Colony forming units (CFU) growth and long term culture-initiating cells (LTC-ICs) were used to test the effects of C817 on humanleukemia progenitor/stem cells. RESULTS: C817 potently inhibited both WT and mutant (Q252H, Y253F, and T315I) Abl kinase activities in a non-ATP competitive manner with the values of IC₅₀ at low nanomole levels. In consistent with above results, C817 suppressed the growth of both imatinib-sensitive and resistant CML cells, including wild-type K562, K562/G01, 32D-T315I, 32D-Q252H, and 32D-Y253F cells with the values of IC₅₀ at low micromole levels. C817 (0.5 or 1 μmol/L) dose-dependently inhibited the phosphorylation of Bcr-Abl and downstream proteins STAT-5 and CrkL in imatinib-resistant K562/G01 cells. Furthermore, C817 significantly suppressed CFU growth and LTC-ICs, implicating that C817 could eradiate humanleukemia progenitor/stem cells. CONCLUSION: C817 is a promising compound for treatment of CMLpatients with Bcr-Abl kinase domain mutations that confer imatinib resistance.
Authors: E Weisberg; X Deng; H G Choi; R Barrett; S Adamia; A Ray; D Moreno; A L Kung; N Gray; J D Griffin Journal: Leukemia Date: 2010-05-27 Impact factor: 11.528
Authors: Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker Journal: J Clin Invest Date: 2010-12-13 Impact factor: 14.808
Authors: Shashidhar S Jatiani; Stephen C Cosenza; M V Ramana Reddy; Ji Hee Ha; Stacey J Baker; Ajoy K Samanta; Matthew J Olnes; Loretta Pfannes; Elaine M Sloand; Ralph B Arlinghaus; E Premkumar Reddy Journal: Genes Cancer Date: 2010-04
Authors: Emmanuelle Passegué; Catriona H M Jamieson; Laurie E Ailles; Irving L Weissman Journal: Proc Natl Acad Sci U S A Date: 2003-09-22 Impact factor: 11.205
Authors: Brian K Adams; Eva M Ferstl; Matthew C Davis; Marike Herold; Serdar Kurtkaya; Richard F Camalier; Melinda G Hollingshead; Gurmeet Kaur; Edward A Sausville; Frederick R Rickles; James P Snyder; Dennis C Liotta; Mamoru Shoji Journal: Bioorg Med Chem Date: 2004-07-15 Impact factor: 3.641
Authors: Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Thomas O'Hare; Denise K Walters; Eric P Stoffregen; Taiping Jia; Paul W Manley; Jürgen Mestan; Sandra W Cowan-Jacob; Francis Y Lee; Michael C Heinrich; Michael W N Deininger; Brian J Druker Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin Journal: Cancer Cell Date: 2005-02 Impact factor: 31.743
Authors: James A McCubrey; Kvin Lertpiriyapong; Linda S Steelman; Steve L Abrams; Li V Yang; Ramiro M Murata; Pedro L Rosalen; Aurora Scalisi; Luca M Neri; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Piotr Laidler; Joanna Dulińska-Litewka; Dariusz Rakus; Agnieszka Gizak; Paolo Lombardi; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Giuseppe Montalto; Melchiorre Cervello Journal: Aging (Albany NY) Date: 2017-06-12 Impact factor: 5.682
Authors: L I Nagy; L Z Fehér; G J Szebeni; M Gyuris; P Sipos; R Alföldi; B Ózsvári; L Hackler; A Balázs; P Batár; I Kanizsai; L G Puskás Journal: Biomed Res Int Date: 2015-05-17 Impact factor: 3.411